Portfolio

Portfolio

Alung Technologies, Inc.

Alung Technologies, Inc. is commercializing a respiratory assist system (RAS). By modeling dialysis, a catheter is placed to remove and return blood simultaneously extracting carbon dioxide and administering oxygen, replacing the need for a ventilator in specific situations. Complications associated with traditional ventilators are reduced and full pay-back to the hospital occurs within the first two weeks of use.

Carmell Therapeutics

Carmell is developing a biologically-active material made from blood plasma that contains a concentration of growth and regenerative factors to accelerate healing. Carmell’s first product is REPAIR™ Bone Putty whose objective is to provide an effective and inexpensive method to accelerate bone healing. There are 1.2M annual fractures of extremities in the U.S. with older adults, diabetic and osteoporotic patients especially have problems with bone healing. Future products will treat injuries to connective tissues (tendons, ligaments and cartilage).

ClearCount Medical Solutions

ClearCount Medical Solutions is the only provider of a sponge management system that combines the benefits of counting and detection utilizing RFID sponges. Roughly 5,000 incidents occur each year in the U.S. in which surgical sponges are retained inside patients due to the lack of an effective tracking system. The results can be disastrous: persistent pain, infection, multiple surgeries and even death. Today less than 2% of the U.S. hospital market has implemented electronic safety technology, representing a large untapped market opportunity.

Cognition Therapeutics

Cognition Therapeutics (CogRx) is a CNS biopharmaceutical company focused on neurodegenerative disorders using proprietary and biologically-relevant screening and chemistry platforms to closely model the pathology of neurodegenerative diseases. Since the first characterization of Alzheimer’s disease (AD) in 1906 by Dr. Alzheimer, there have been no tangible advances in finding drugs to halt or prevent disease progression. The Founders of CogRx believe that the current “target-driven” methods of drug discovery used by pharmaceutical companies are not ideal for identifying disease modifying drugs.

Cohera Medical, Inc.

Cohera has recently launched its lead product, TissuGlu™, in select EU markets, starting with its target application in plastic surgery. The company intends to achieve the following product development milestones over the next year; chemical characterization studies in support of an IDE submission with the U.S. FDA, biocompatibility testing to establish product safety, perform pre-clinical tests and establish manufacturing and sterilization protocols for implementation at a GMP facility. The company has recently secured CE marking and human clinical trials have been completed in Germany. Revenue is now being generated in the EU.

Medrobotics

The inhibitor to Minimally Invasive Surgery (MIS) procedural expansion is that endoscopes (flexible tubes) can rarely be used for surgery. Their unstable (floppy) platform provides insufficient support to control the therapeutic end of the tool – thus straight tubes (laparoscopes) are primarily used in therapeutic situations. Medrobotics has developed the technology breakthrough required to combine the benefits of both technologies to navigate to non-linear regions and allow for therapeutic action. The potential impact is to reignite the multi-billion dollar MIS marketplace back to double-digit growth rates.

Quantum Ops

Quantum OPS is a revenue generating orthopedic surgical device company. Their lead technology, QSP7TM, is a uniquely designed device that facilitates effortless, rapid and secure positioning of patients of all sizes for all types of shoulder surgery. The QSP7TM positioning system is a simple, safe, effective and user friendly device that addresses 3 decades worth of frustrations and complaints from surgeons, nurses and anesthesiologists. Its first product, the QSP 7 Shoulder Positioner, was hard launched January 1, 2012 after a successful beta launch in September, 2011.

Rinovum

Rinovum is an early-stage direct to consumer medical device company focused on reproductive health to aid in natural fertility and conception in the privacy of the couple’s home. The company’s mission is to give women/couples healthcare products that will assist them in reaching their reproductive goals.

Comments are closed.